MDC Stock Overview
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.
+ 2 more risks
Medlab Clinical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$11.02|
|52 Week High||AU$30.00|
|52 Week Low||AU$6.45|
|1 Month Change||-16.52%|
|3 Month Change||36.05%|
|1 Year Change||-51.02%|
|3 Year Change||-83.49%|
|5 Year Change||-89.51%|
|Change since IPO||-63.27%|
Recent News & Updates
|MDC||AU Biotechs||AU Market|
Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -5% over the past year.
Return vs Market: MDC underperformed the Australian Market which returned -10.6% over the past year.
|MDC Average Weekly Movement||16.0%|
|Biotechs Industry Average Movement||10.4%|
|Market Average Movement||9.6%|
|10% most volatile stocks in AU Market||16.8%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: MDC is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: MDC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.
Medlab Clinical Fundamentals Summary
|MDC fundamental statistics|
Is MDC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDC income statement (TTM)|
|Cost of Revenue||AU$336.29k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.64|
|Net Profit Margin||-648.93%|
How did MDC perform over the long term?See historical performance and comparison
Is MDC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MDC?
Other financial metrics that can be useful for relative valuation.
|What is MDC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does MDC's PS Ratio compare to its peers?
|MDC PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
MDC Medlab Clinical
Price-To-Sales vs Peers: MDC is good value based on its Price-To-Sales Ratio (19.6x) compared to the peer average (21.1x).
Price to Earnings Ratio vs Industry
How does MDC's PE Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Sales vs Industry: MDC is good value based on its Price-To-Sales Ratio (19.6x) compared to the Australian Biotechs industry average (19.9x)
Price to Sales Ratio vs Fair Ratio
What is MDC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||19.6x|
|Fair PS Ratio||19.6x|
Price-To-Sales vs Fair Ratio: MDC is expensive based on its Price-To-Sales Ratio (19.6x) compared to the estimated Fair Price-To-Sales Ratio (19.6x).
Share Price vs Fair Value
What is the Fair Price of MDC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MDC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MDC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Medlab Clinical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDC's revenue (51.1% per year) is forecast to grow faster than the Australian market (3.7% per year).
High Growth Revenue: MDC's revenue (51.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Medlab Clinical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDC is currently unprofitable.
Growing Profit Margin: MDC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.3%).
Return on Equity
High ROE: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.
Discover strong past performing companies
How is Medlab Clinical's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MDC's short term assets (A$9.2M) exceed its short term liabilities (A$2.9M).
Long Term Liabilities: MDC's short term assets (A$9.2M) exceed its long term liabilities (A$740.8K).
Debt to Equity History and Analysis
Debt Level: MDC is debt free.
Reducing Debt: MDC has no debt compared to 5 years ago when its debt to equity ratio was 9.9%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MDC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.7% each year
Discover healthy companies
What is Medlab Clinical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Medlab Clinical Dividend Yield vs Market|
|Company (Medlab Clinical)||n/a|
|Market Bottom 25% (AU)||2.8%|
|Market Top 25% (AU)||7.2%|
|Industry Average (Biotechs)||2.7%|
|Analyst forecast in 3 Years (Medlab Clinical)||0%|
Notable Dividend: Unable to evaluate MDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Sean Michael Hall serves as the Chief Executive Officer at Medlab Clinical Limited and served as its Managing Director. He served as a Managing Director of Medlab Clinical Limited until November 2020....
CEO Compensation Analysis
|Sean Hall's Compensation vs Medlab Clinical Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||AU$574k||AU$441k|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||AU$677k||AU$372k|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||AU$379k||AU$300k|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||AU$364k||AU$299k|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||AU$328k||AU$299k|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||AU$328k||AU$299k|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||AU$328k||AU$299k|
Compensation vs Market: Sean's total compensation ($USD369.89K) is above average for companies of similar size in the Australian market ($USD274.98K).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Experienced Board: MDC's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MDC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|08 Jul 22||BuyAU$10,000||Sean Hall||Individual||832.14||AU$12.02|
|12 Apr 22||BuyAU$10,000||Sean Hall||Individual||832.14||AU$12.02|
|04 Apr 22||BuyAU$10,000||Sean Hall||Individual||732.6||AU$13.65|
|30 Mar 22||BuyAU$8,997||Sean Hall||Individual||638.29||AU$14.10|
|04 Nov 21||BuyAU$18,000||Sean Hall||Individual||666.67||AU$27.00|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Medlab Clinical Limited's employee growth, exchange listings and data sources
- Name: Medlab Clinical Limited
- Ticker: MDC
- Exchange: ASX
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$25.164m
- Shares outstanding: 2.28m
- Website: https://www.medlab.co
- Medlab Clinical Limited
- Building A
- Unit A5 – A6, Botany Quarter
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MDC||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jul 2015|
|MDC||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jul 2015|
|MDBB.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jul 2015|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.